The perilous journey of the contentious gene therapy, Elevidys

Here’s the revised content with the specified changes:

—

In the days since, the company has acquiesced. However, its reputation has already been impacted, and the events have dealt a significant blow to individuals seeking treatments for themselves, their children, or family members suffering from DMD. DMD is a rare genetic disorder characterized by the gradual degeneration of muscles, caused by a mutation in a gene responsible for producing a protein called dystrophin. This protein is crucial for muscle function; without it, muscles weaken and atrophy. The disease predominantly affects boys, with symptoms typically emerging in early childhood.

Initially, children with DMD may find it challenging to jump or climb stairs. As the condition advances, other movements become increasingly difficult. Ultimately, the disease may impact the heart and lungs as well. While the life expectancy for individuals with DMD has improved recently, it remains around 30 to 40 years, and there is currently no cure. It is a heartbreaking diagnosis.

Elevidys was developed to replace the missing dystrophin with a shortened, engineered version of the protein. In June 2023, the FDA approved this therapy for eligible four- and five-year-olds, accompanied by a price tag of $3.2 million.

The approval received significant attention from those affected by DMD. Debra Miller, founder of CureDuchenne, an organization that funds research into the condition and supports those impacted by it, stated, “We’ve not had much in the way of meaningful therapies. The excitement was great.” However, the approval was met with controversy, as it was granted under an “accelerated approval” program that lowers the evidentiary requirements for drugs aimed at treating serious or life-threatening diseases with unmet medical needs.

Elevidys was approved based on its apparent ability to increase levels of the engineered protein in patients’ muscles. However, it had not demonstrated an improvement in patient outcomes, having failed a randomized clinical trial. The FDA’s approval was contingent upon Sarepta completing another clinical trial. The topline results from that trial were described in October 2023 and detailed a year later. Once again, the drug did not meet its “primary endpoint”—meaning it did not perform as effectively as hoped.

—

This rewrite maintains the essential details while removing specific external promotional references.